skin model for subcutaneous injections
NEW SUBCUTANEOUS STUDY MODEL
HypoSkin is currently the only alternative to animal testing for subcutaneous injections.
REAL HUMAN SKIN STRUCTURE
The HypoSkin model contains all three layers of human skin for predictive studies.
LIVE HUMAN SKIN RESPONSE
Genoskin’s patented matrix and culture medium keep the skin model alive for up to 7 days.
PROJECT UNDER DEVELOPMENT
HypoSkin is currently under development with promising results.
The only human skin model to study subcutaneous injections
Genoskin is developing an ex vivo human skin biopsy with fat tissue. HypoSkin contains the three layers of the skin: epidermis, dermis and hypodermis. Currently, many of the compounds that are under development or already on the market are administrated subcutaneously, such as cancer treatments, anti-inflammatory agents or cosmetic fillers. HypoSkin is an ex vivo model to study compound absorption, first-pass catabolism and toxicity in the subcutaneous tissue.
The need for in vitro models for subcutaneous administration
To date, there are no in vitro biological models to test the effects of compound injection in the subcutaneous tissue. Formulations are generally tested in vivo on animals, even though their skin and subcutaneous fat tissue are different from humans. The absence of more pertinent models makes it difficult to evaluate and optimize a compound’s formulation before clinical trials. To develop efficient drugs for subcutaneous injection, there’s a strong need for in vitro experimental models that closely mimic human tissue structure and physiology.